6Suppliers
2Customers
1Debt Items
20Related Chains

Cellectis S.A. Suppliers

TickerNameConfidenceEvidence
ALLOGENE ALLOGENE 90% We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca under which our partners have or have the right to obtain exclusive development and…
AZN AstraZeneca PLC 90% We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca under which our partners have or have the right to obtain exclusive development and…
AZN AstraZeneca PLC 90% Reciprocal relationship from AZN graph: Reciprocal relationship from CLLS graph: We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca un…
SERVIER SERVIER 90% We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca under which our partners have or have the right to obtain exclusive development and…
INSTITUT-DE-RECHERCHES-INTERNATIONALES-SERVIER-S INSTITUT-DE-RECHERCHES-INTERNATIONALES-SERVIER-S 80% Under the License, Development and Commercialization Agreement dated March 6, 2019, between us and Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, "…
LES-LABORATOIRES-SERVIER-SAS LES-LABORATOIRES-SERVIER-SAS 80% Under the License, Development and Commercialization Agreement dated March 6, 2019, between us and Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, "…

Cellectis S.A. Customers

TickerNameConfidenceEvidence
IOVA Iovance Biotherapeutics, Inc. 85% Reciprocal relationship from IOVA graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from IOVA g…
PGEN Precigen, Inc. 72% Reciprocal relationship from PGEN graph: ions will be subject to FCPA, which prohibits, among other things, United States companies and their employees and agents from authorizing, promising, offerin…

Cellectis S.A. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CLLS-DEBT Debt stack $32.2M 90% Market cache reports total debt of $32.2M.

Cellectis S.A. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cellectis S.A..

Cellectis S.A. Ownership

HolderNameConfidenceEvidence
CLLS-OWNER-B-GROUP-INC B Group, Inc. 90% 13F overlay lists B Group, Inc. as top holder; 33 tracked holders.

Cellectis S.A. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
TLSA Tiziana Life Sciences Ltd 100.00 2
SDGR Schrödinger, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BTAI BioXcel Therapeutics, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
CLYM Climb Bio, Inc. 100.00 2
BEAM Beam Therapeutics Inc. 100.00 2
DTIL Precision BioSciences, Inc. 100.00 1 ['receiving', 'spend']
AZN AstraZeneca PLC 100.00 2 ['supplier']
CHRS Coherus Oncology, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
CRBU Caribou Biosciences, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 1 ['receiving', 'spend']
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2